Expanding RNA Druggability with Small Molecules
As the first small-molecule drug targeting RNA gains momentum, the ability to design small molecules capable of interacting with and modulating RNA is opening as a new avenue to target challenging disease pathways that have previously been considered undruggable.
The 4th RNA-Targeted Drug Discovery Summit is returning once again this December, to reunite the largest community of thought leaders and experts in Biology, Chemistry and RNA Therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties.
Join the leading RNA small molecule forum alongside 200+ biopharmaceutical Directors, VPs and C-level Executives to hear the latest pioneering case studies and successfully translate your discovery and pre-clinical strategies into robust pipelines of RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field.
We’re back in 2021 with a more comprehensive program than ever & we’d love you to join us whether in-person in Boston or virtually!